HA130

Technical Properties

The HA130 hemoperfusion cartridge by Jafron is a highly effective solution for treating patients with conditions where excessive inflammation is a concern. It offers the following technical properties:

• Adsorbent Volume: 130 ml
• Biocompatibility: Tested as required in ISO 10993
• Adsorbent Material: Double cross-linked styrene-divinylbenzene copolymers
• Housing Material: Polycarbonate
• Sterilization Method: Irradiation sterilization
• Unit Package Dimensions: 1952mm (L) x 1102mm (W) x 1105mm (H)

The adsorbent volume of 130 ml is designed to efficiently remove inflammatory mediators from the bloodstream, providing relief to patients suffering from conditions such as sepsis, acute respiratory distress syndrome (ARDS), and drug overdose. The biocompatibility of the cartridge has been thoroughly tested according to ISO 10993 standards to ensure its safety and compatibility with the human body.

The adsorbent material used in the HA130 cartridge is made of double cross-linked styrene-divinylbenzene copolymers, which have been proven to have high adsorption capacity and excellent stability. This material allows for the effective removal of a wide range of inflammatory molecules, including cytokines, endotoxins, and bilirubin.

The housing material of the cartridge is made of polycarbonate, a durable and heat-resistant material that ensures the structural integrity of the cartridge during use. The polycarbonate housing also provides protection to the adsorbent material, preventing any leakage or contamination.

To ensure the sterility of the cartridge, it undergoes irradiation sterilization, a widely accepted method that effectively eliminates any potential pathogens or microorganisms. This sterilization method ensures that each cartridge is safe for use and free from any harmful contaminants.

The unit package dimensions of the HA130 cartridge are 1952mm (L) x 1102mm (W) x 1105mm (H), providing a compact and space-saving design. This allows for easy storage and transportation of the cartridges, ensuring that they are readily available when needed.

Clinical Benefits

The HA130 hemoperfusion cartridge provides a range of clinical benefits for patients undergoing treatment. These benefits include:

• Adsorption of Middle and Protein-bound Uremic Toxins: The HA130 cartridge is designed to effectively adsorb middle and protein-bound uremic toxins, such as PTH, leptin, and (3,-mg). This helps in the management of conditions associated with uremia.
• Improved Renal Function: By removing middle and protein-bound uremic toxins, the HA130 cartridge aids in improving renal function. These toxins, if left unremoved, can accumulate in the body and put additional strain on the kidneys. By reducing their levels, the cartridge helps alleviate this burden and allows the kidneys to function more efficiently.
• Enhanced Quality of Life: Patients undergoing treatment with the HA130 hemoperfusion cartridge often experience an improvement in their overall quality of life. The removal of uremic toxins can alleviate symptoms such as fatigue, nausea, and loss of appetite, allowing patients to feel better and engage in daily activities with greater ease.
• Reduced Cardiovascular Risk: Uremic toxins have been linked to an increased risk of cardiovascular disease. By effectively adsorbing these toxins, the HA130 cartridge helps reduce cardiovascular risk factors in patients with kidney disease. This can lead to a lower incidence of heart attacks, strokes, and other cardiovascular events.
• Prevention of Complications: Uremia is associated with various complications, including bone disease, anemia, and immune dysfunction. The HA130 cartridge’s ability to remove uremic toxins can help prevent or mitigate these complications, improving overall patient outcomes and reducing the need for additional interventions.

Overall, the HA130 hemoperfusion cartridge offers a comprehensive approach to the management of uremia and its associated complications. By effectively adsorbing middle and protein-bound uremic toxins, it helps improve renal function, enhance quality of life, reduce cardiovascular risk, and prevent complications. This innovative treatment option holds great promise for patients with kidney disease, providing them with a better chance at a healthier and more fulfilling life.

Clinical Indications

The HA130 hemoperfusion cartridge is recommended for use in the treatment of the following clinical indications:

• End-Stage Renal Disease (ESRD): The HA130 cartridge can be used to effectively manage patients with ESRD, helping to remove toxins and improve overall renal function. This is particularly important for patients who are not eligible for or do not respond well to kidney transplantation.
• Skin Itching: Patients suffering from skin itching due to conditions like uremia can benefit from the HA130 cartridge, as it helps in the removal of toxins that contribute to the itching sensation. This can greatly improve the quality of life for these patients, reducing discomfort and allowing them to engage in daily activities without constant itching.
• Renal Osteodystrophy: The HA130 cartridge aids in the management of renal osteodystrophy, a condition characterized by bone abnormalities in patients with chronic kidney disease. By removing uremic toxins that contribute to bone loss and abnormalities, the cartridge helps to improve bone health and minimize the risk of fractures.
• Cardiovascular Disease: By removing inflammatory mediators from the bloodstream, the HA130 cartridge can help reduce inflammation and improve cardiovascular health in patients with cardiovascular disease. This can lead to a reduction in the risk of heart attacks, strokes, and other cardiovascular events, ultimately improving the prognosis for these patients.
• Refractory Hypertension: The HA130 cartridge can be used as an adjunctive therapy in the management of refractory hypertension, helping to reduce inflammation and improve blood pressure control. This is particularly beneficial for patients who do not respond well to traditional antihypertensive medications, providing an alternative treatment option to improve their blood pressure management.
• Microinflammatory State: Patients with conditions characterized by a microinflammatory state, such as sepsis or systemic inflammatory response syndrome (SIRS), can benefit from the HA130 cartridge, as it helps in the removal of inflammatory mediators. This can help to reduce the severity of the inflammatory response and improve the overall prognosis for these patients.
• Malnutrition: The HA130 cartridge can aid in the management of malnutrition in patients with chronic kidney disease, as it helps remove toxins that contribute to poor appetite and nutrient absorption. By improving the nutritional status of these patients, the cartridge can help to prevent further complications and improve overall health outcomes.
• Insomnia: By reducing inflammation and removing toxins, the HA130 cartridge can contribute to improved sleep quality in patients with insomnia associated with chronic kidney disease. This can lead to better restorative sleep, improved daytime functioning, and an overall improvement in the quality of life for these patients.

With its biocompatibility tested as required in ISO 10993 and polycarbonate housing material, the HA130 hemoperfusion cartridge is a reliable and safe solution for treating inflammatory diseases. Its selective adsorption properties and ability to remove uremic toxins make it an effective treatment option for a wide range of clinical indications. Whether it is managing ESRD, alleviating skin itching, improving cardiovascular health, or addressing malnutrition, the HA130 cartridge offers a versatile and valuable treatment option for patients in need.